<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791491</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-144</org_study_id>
    <secondary_id>2011-005257-31</secondary_id>
    <nct_id>NCT01791491</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients</brief_title>
  <official_title>A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how well adolescent kidney transplant patients
      tolerate a single dose of belatacept they receive at least 6 months after transplant
      surgery, and how their body handles the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T-HALF)</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady-state (Vss)</measure>
    <time_frame>7 time points following SD administration up to Day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be measured by proportion of subjects reporting Adverse Event (AE), Serious AE, and AE leading to early discontinuation</measure>
    <time_frame>BL/Day 1, Days 8, 15, 29 and 57, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against Belatacept</measure>
    <time_frame>Day 1, 15, 29, and 57 in SD phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD86 receptor occupancy in Blood samples</measure>
    <time_frame>Day1, 29 and 57 in SD phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability will be measured by proportion of subjects reporting Adverse Event (AE), Serious AE, and AE leading to early discontinuation</measure>
    <time_frame>BL/Day 1, Days 8, 15, 29 and 57, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Single intravenous infusion of belatacept, 7.5 mg/kg</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>BMS-224818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male and Female subjects,12-17 years old

          -  Receiving CNI-based maintenance immunosuppression since the time of renal
             transplantation in accordance with local standard of care

          -  Stable renal function, in the opinion of the investigator, with a cGFR&gt;45
             mL/min/1.73m2 at the time of enrollment (per updated Schwartz Formula)

          -  Adolescent Recipients of a renal allograft from a living donor or a deceased donor at
             least 6 months prior to enrollment

          -  Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA)
             [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen

          -  Subject must be receiving adjunctive background maintenance immunosuppression with
             mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium
             (EC-MPS)/mycophenolic acid (MPA)

          -  Subjects may be receiving maintenance corticosteroids in accordance with the local
             standard of care

          -  Negative Interferon Gamma Release Assay (IGRA) such as QuantiFERON-TB Gold test or
             T-Spot-TB

          -  FOCBP must have negative serum or urine pregnancy test within 24 hrs prior to start
             of study medication

          -  Subject must have stable estimated glomerular filtration rate (GFR) â‰¥45 mL/min/1.73m2
             (updated Schwartz formula)

        Exclusion Criteria:

          -  Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and
             screening

          -  History of any treated or biopsy proven acute rejection (BPAR) within 3 months prior
             to enrollment

          -  Subjects who have experienced more than 1 episode of acute rejection (AR) of the
             current allograft or any antibody-mediated AR

          -  Significant proteinuria

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>District of Columbia</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
